UNSPSC 51381510: Flufenamic acid

This classification denotes an anti-inflammatory agent with the molecular formula C14H10F3NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 60GCX7Y6BH, chemically known as n-(alpha,alpha,alpha-trifluoro-m-tolyl)anthranilic acid but generally known as flufenamic acid, which bears US NIH Compound Identifier 3371. European Medicines Agency schedules Flufenamic acid in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07686MIG.

World Health Organization schedules flufenamic acid in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule flufenamic acid under HS 29224995 and SITC 51465. As of Q4 2014, FLUFENAMIC ACID remains the US FDA Preferred Term for this commodity. SMILES: FC(F)(F)C1CC(NC2C(CCCC2)C(=O)O)CCC1.

UNSPSC 51381510 Flufenamic acid is a Commodity code that nominally identifies a nonsteroidal anti-inflammatory drug; however, the recent state and local opportunities posted under this code show little alignment with flufenamic acid specifically. Instead, the opportunities reflect broader pharmaceutical procurement activity—naloxone and drug deactivation systems, generic multi-source pharmaceuticals and over-the-counter products, and direct-to-manufacturer prescription programs. The code appears to be misapplied or used as a catch-all within state procurement systems for pharmaceutical and medical supply sourcing more broadly, rather than capturing purchases of flufenamic acid itself. State and local issuing bodies soliciting pharmaceutical products under this code include county health departments, state health and human services commissions, and multistate cooperative purchasing alliances. Issuing bodies range from single counties to multi-jurisdictional cooperative vehicles serving state agencies and local government facilities across multiple states.

Activity under this code appears concentrated in the South and Upper Midwest, with recent solicitations from Seminole County, Florida; the Texas Health and Human Services Commission; and the Minnesota Multistate Cooperative Purchasing Alliance (which serves participating states including Oregon). Representative opportunities include Seminole County's IFB 60459723LAS, posted June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with a response deadline of July 26, 2023; MMCAP's RFP S1070000015802, posted January 20, 2026, for generic multi-source pharmaceuticals and OTC products with a March 26, 2026 proposal deadline; and the Texas HHS Commission's RFI HHS0017013, posted April 3, 2026, exploring direct-to-manufacturer prescription programs. The code's recent activity suggests state and local governments are actively procuring pharmaceutical products and related medical supplies, though the mismatch between the nominal commodity (flufenamic acid) and the actual opportunities posted suggests business development professionals should verify the code's accuracy before pursuing opportunities or should expect broader pharmaceutical sourcing rather than a single active pharmaceutical ingredient.